Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2022-06-13 | Forward | 4:1 |
| 2022-06-10 | Forward | 4:1 |
DexCom, Inc. develops and commercializes continuous glucose monitoring systems for people with diabetes and healthcare providers worldwide, including products like G6, G7, and remote monitoring solutions.

The Dexcom G7 15-Day is a long-lasting continuous glucose monitor for adults with diabetes, providing up to 15 days of real-time, accurate glucose readings to improve convenience and reduce sensor changes.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $851.9M | — | — | — |
![]() | NonUS | $357.4M | $368.1M ▲ | $359.6M ▼ | $375M ▲ |
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
TEVA | $36.00 | COMPARE |
BIIB | $217.80 | COMPARE |
WAT | $411.76 | COMPARE |
LH | $333.07 | COMPARE |
PHG | $26.60 | COMPARE |
WST | $341.02 | COMPARE |
STE | $232.23 | COMPARE |
ZBH | $100.24 | COMPARE |